Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications

P. Vlček, J. Polák, M. Brunovský, J. Horáček,

. 2018 ; 51 (6) : 229-242. [pub] 20170926

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19001171

Grantová podpora
NV15-29370A MZ0 CEP - Centrální evidence projektů
NV15-34524A MZ0 CEP - Centrální evidence projektů

Obsessive-compulsive disorder (OCD) is a chronic psychiatric illness and 1 of the most common anxiety disorders with the prevalence of 3%. Although its pathogenesis remains unclear, the traditional model focused on alternations in the serotonin system. Selective serotonin reuptake inhibitors provide the most effective treatment; however, as much as 40-60% of patients do not respond to antidepressants therapy. Thus, attention has shifted towards other neurotransmitter systems and related neuroanatomical structures. Recently, there is extensive evidence showing a key role of glutamate pathways abnormalities within the cortico-striatal-thalamo-cortical circuitry and temporal lobes in OCD pathogenesis. In this review, we link together the existent neuroanatomical, neurophysiological, and neuropsychological evidence to argue for potential benefits of adjuvant treatment with glutamatergic agents, especially memantine. By a targeted de-excitation effect on the glutamatergic system in the temporal lobes and connected brain regions, memantine might further alleviate OCD symptoms. This effect should be even more pronounced in certain subtypes of patients with specific cognitive deficits and maladaptive compensatory memory processes (e.g., checkers).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19001171
003      
CZ-PrNML
005      
20201116114529.0
007      
ta
008      
190107s2018 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1055/s-0043-118665 $2 doi
035    __
$a (PubMed)28950396
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Vlček, Přemysl, $d 1978- $7 xx0233915 $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic. Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Prague 10, Czech Republic.
245    10
$a Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications / $c P. Vlček, J. Polák, M. Brunovský, J. Horáček,
520    9_
$a Obsessive-compulsive disorder (OCD) is a chronic psychiatric illness and 1 of the most common anxiety disorders with the prevalence of 3%. Although its pathogenesis remains unclear, the traditional model focused on alternations in the serotonin system. Selective serotonin reuptake inhibitors provide the most effective treatment; however, as much as 40-60% of patients do not respond to antidepressants therapy. Thus, attention has shifted towards other neurotransmitter systems and related neuroanatomical structures. Recently, there is extensive evidence showing a key role of glutamate pathways abnormalities within the cortico-striatal-thalamo-cortical circuitry and temporal lobes in OCD pathogenesis. In this review, we link together the existent neuroanatomical, neurophysiological, and neuropsychological evidence to argue for potential benefits of adjuvant treatment with glutamatergic agents, especially memantine. By a targeted de-excitation effect on the glutamatergic system in the temporal lobes and connected brain regions, memantine might further alleviate OCD symptoms. This effect should be even more pronounced in certain subtypes of patients with specific cognitive deficits and maladaptive compensatory memory processes (e.g., checkers).
650    _2
$a mozek $x účinky léků $x metabolismus $7 D001921
650    _2
$a kognitivní poruchy $x etiologie $7 D003072
650    _2
$a látky působící na systém excitačních aminokyselin $x terapeutické užití $7 D018683
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a kyselina glutamová $x metabolismus $7 D018698
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a neuropsychologické testy $7 D009483
650    _2
$a obsedantně kompulzivní porucha $x komplikace $x farmakoterapie $x metabolismus $x patologie $7 D009771
650    _2
$a glutamátové receptory $x metabolismus $7 D017470
655    _2
$a časopisecké články $7 D016428
700    1_
$a Polák, Jakub, $d 1982- $7 jo2007251135 $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic.
700    1_
$a Brunovský, Martin $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic. Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Prague 10, Czech Republic.
700    1_
$a Horáček, Jiří $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic. Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Prague 10, Czech Republic.
773    0_
$w MED00003796 $t Pharmacopsychiatry $x 1439-0795 $g Roč. 51, č. 6 (2018), s. 229-242
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28950396 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20201116114529 $b ABA008
999    __
$a ok $b bmc $g 1365078 $s 1039294
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 51 $c 6 $d 229-242 $e 20170926 $i 1439-0795 $m Pharmacopsychiatry $n Pharmacopsychiatry $x MED00003796
GRA    __
$a NV15-29370A $p MZ0
GRA    __
$a NV15-34524A $p MZ0
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...